{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:31:44Z","timestamp":1793410304321,"version":"4.5.0"},"reference-count":229,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82074360"],"award-info":[{"award-number":["82074360"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatocellular carcinoma (HCC) remains a critical global health concern, particularly in regions with high endemicity of hepatitis B, hepatitis C, and non-alcoholic fatty liver disease. Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has emerged as a promising therapeutic strategy for advanced HCC. Despite encouraging results, primary and acquired resistance to ICIs continues to pose significant challenges in clinical practice. Recent research has identified tumor-associated macrophages (TAMs) as key contributors to immune evasion and ICI resistance in HCC, primarily through polarization to the M2 phenotype. M2-polarized TAMs secrete a range of immunosuppressive cytokines that inhibit T cell activation and promote tumor progression through processes such as angiogenesis and epithelial-mesenchymal transition. These mechanisms compromise the efficacy of ICIs and facilitate tumor expansion and metastasis. This review summarizes the role of TAM-related signaling pathways in driving immune evasion and ICI resistance in HCC, with particular emphasis on the contribution of TAM surface receptors and chemokines in immune suppression. Additionally, the review highlights emerging insights into TAM metabolic reprogramming and transcriptional regulation, which have been closely linked to ICI resistance. Furthermore, we explore promising therapeutic strategies targeting TAMs and their associated signaling pathways to enhance ICI efficacy in HCC. Integrating these novel approaches could potentially overcome TAM-driven immune evasion and ICI resistance, boosting the efficacy of immunotherapy and improving patient prognosis in HCC.<\/jats:p>","DOI":"10.1186\/s13046-025-03490-9","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T05:44:34Z","timestamp":1754372674000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma"],"prefix":"10.1186","volume":"44","author":[{"given":"Fen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"issue":"3","key":"3490_CR1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.21147\/j.issn.1000-9604.2023.03.06","volume":"35","author":"G Yang","year":"2023","unstructured":"Yang G, Yan H, Tang Y, Yuan F, Cao M, Ren Y, Li Y, He Z, Su X, Yao Z, et al. Advancements in Understanding mechanisms of hepatocellular carcinoma radiosensitivity: A comprehensive review. Chin J Cancer Res. 2023;35(3):266\u201382.","journal-title":"Chin J Cancer Res"},{"issue":"2","key":"3490_CR2","doi-asserted-by":"publisher","first-page":"102446","DOI":"10.1016\/j.jceh.2024.102446","volume":"15","author":"SP Singh","year":"2025","unstructured":"Singh SP, Madke T, Chand P. Global epidemiology of hepatocellular carcinoma. J Clin Exp Hepatol. 2025;15(2):102446.","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"3490_CR3","doi-asserted-by":"publisher","first-page":"2455539","DOI":"10.1080\/07853890.2025.2455539","volume":"57","author":"J Wang","year":"2025","unstructured":"Wang J, Qiu K, Zhou S, Gan Y, Jiang K, Wang D, Wang H. Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis. Ann Med. 2025;57(1):2455539.","journal-title":"Ann Med"},{"key":"3490_CR4","doi-asserted-by":"crossref","unstructured":"Khare T, Liu K, Chilambe LO, Khare S. NAFLD and NAFLD related HCC: emerging treatments and clinical trials. Int J Mol Sci 2025, 26(1).","DOI":"10.3390\/ijms26010306"},{"issue":"10360","key":"3490_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u201362.","journal-title":"Lancet"},{"key":"3490_CR6","doi-asserted-by":"crossref","unstructured":"Yang H, Liu Y, Zhang N, Tao F, Yin G. Therapeutic advances in hepatocellular carcinoma: an update from the 2024 ASCO annual meeting. Front Oncol. 2024;14:1453412.","DOI":"10.3389\/fonc.2024.1453412"},{"key":"3490_CR7","doi-asserted-by":"crossref","unstructured":"Hwang SY, Danpanichkul P, Agopian V, Mehta N, Parikh ND, Abou-Alfa GK, Singal AG, Yang JD. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clin Mol Hepatol 2024.","DOI":"10.3350\/cmh.2024.0824"},{"issue":"15","key":"3490_CR8","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.23.02745","volume":"42","author":"JD Gordan","year":"2024","unstructured":"Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, Goff L, Gupta S, Guy J, Hoang HT, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J Clin Oncol. 2024;42(15):1830\u201350.","journal-title":"J Clin Oncol"},{"key":"3490_CR9","doi-asserted-by":"crossref","unstructured":"Krupa K, Fudalej M, Cencelewicz-Lesikow A, Badowska-Kozakiewicz A, Czerw A, Deptala A. Current Treatment Methods in Hepatocellular Carcinoma. Cancers (Basel). 2024, 16(23).","DOI":"10.3390\/cancers16234059"},{"issue":"12","key":"3490_CR10","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1007\/s00262-023-03568-3","volume":"72","author":"L Kou","year":"2023","unstructured":"Kou L, Xie X, Chen X, Li B, Li J, Li Y. The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma. Cancer Immunol Immunother. 2023;72(12):3953\u201369.","journal-title":"Cancer Immunol Immunother"},{"key":"3490_CR11","doi-asserted-by":"crossref","unstructured":"Giannone G, Ghisoni E, Genta S, Scotto G, Tuninetti V, Turinetto M, Valabrega G. Immuno-Metabolism and microenvironment in cancer: key players for immunotherapy. Int J Mol Sci 2020, 21(12).","DOI":"10.3390\/ijms21124414"},{"issue":"10","key":"3490_CR12","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s43018-024-00828-8","volume":"5","author":"L Lemaitre","year":"2024","unstructured":"Lemaitre L, Adeniji N, Suresh A, Reguram R, Zhang J, Park J, Reddy A, Trevino AE, Mayer AT, Deutzmann A, et al. Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease. Nat Cancer. 2024;5(10):1534\u201356.","journal-title":"Nat Cancer"},{"issue":"11","key":"3490_CR13","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1158\/0008-5472.CAN-23-3106","volume":"84","author":"J Weng","year":"2024","unstructured":"Weng J, Wang Z, Hu Z, Xu W, Sun JL, Wang F, Zhou Q, Liu S, Xu M, Xu M, et al. Repolarization of immunosuppressive macrophages by targeting SLAMF7-Regulated CCL2 signaling sensitizes hepatocellular carcinoma to immunotherapy. Cancer Res. 2024;84(11):1817\u201333.","journal-title":"Cancer Res"},{"key":"3490_CR14","doi-asserted-by":"crossref","unstructured":"Zhang Y, Rao Y, Lu J, Wang J, Ker DFE, Zhou J, Wang DM. The influence of biophysical niche on tumor-associated macrophages in liver cancer. Hepatol Commun 2024, 8(11).","DOI":"10.1097\/HC9.0000000000000569"},{"issue":"5","key":"3490_CR15","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.7150\/jca.51346","volume":"12","author":"Y Huang","year":"2021","unstructured":"Huang Y, Ge W, Zhou J, Gao B, Qian X, Wang W. The role of tumor associated macrophages in hepatocellular carcinoma. J Cancer. 2021;12(5):1284\u201394.","journal-title":"J Cancer"},{"issue":"1","key":"3490_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13578-022-00823-5","volume":"12","author":"M Li","year":"2022","unstructured":"Li M, He L, Zhu J, Zhang P, Liang S. Targeting tumor-associated macrophages for cancer treatment. Cell Biosci. 2022;12(1):85.","journal-title":"Cell Biosci"},{"issue":"9","key":"3490_CR17","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.7150\/thno.95971","volume":"14","author":"Y Li","year":"2024","unstructured":"Li Y, Li F, Xu L, Shi X, Xue H, Liu J, Bai S, Wu Y, Yang Z, Xue F, et al. Single cell analyses reveal the PD-1 Blockade response-related immune features in hepatocellular carcinoma. Theranostics. 2024;14(9):3526\u201347.","journal-title":"Theranostics"},{"issue":"2","key":"3490_CR18","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3892\/ol.2020.11726","volume":"20","author":"B Cui","year":"2020","unstructured":"Cui B, Fan X, Zhou D, He L, Li Y, Li D, Lin H. CSF1R methylation is a key regulatory mechanism of tumor-associated macrophages in hepatocellular carcinoma. Oncol Lett. 2020;20(2):1835\u201345.","journal-title":"Oncol Lett"},{"issue":"20","key":"3490_CR19","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1039\/D4TB00230J","volume":"12","author":"C Liang","year":"2024","unstructured":"Liang C, Zhang Y, Wang S, Jiao W, Guo J, Zhang N, Liu X. Nanomaterials in modulating tumor-associated macrophages and enhancing immunotherapy. J Mater Chem B. 2024;12(20):4809\u201323.","journal-title":"J Mater Chem B"},{"key":"3490_CR20","unstructured":"Cappuyns S, Pique-Gili M, Esteban-Fabro R, Philips G, Balaseviciute U, Pinyol R, Gris-Oliver A, Vandecaveye V, Abril-Fornaguera J, Montironi C et al. Single-cell RNA seq-derived signatures define response patterns to atezolizumab\u2009+\u2009bevacizumab in advanced hepatocellular carcinoma. J Hepatol 2024."},{"key":"3490_CR21","doi-asserted-by":"crossref","unstructured":"Ou DL, Chen CW, Hsu CL, Chung CH, Feng ZR, Lee BS, Cheng AL, Yang MH, Hsu C. Regorafenib enhances antitumor immunity via Inhibition of p38 kinase\/Creb1\/Klf4 axis in tumor-associated macrophages. J Immunother Cancer 2021, 9(3).","DOI":"10.1136\/jitc-2020-001657"},{"issue":"2","key":"3490_CR22","doi-asserted-by":"publisher","first-page":"832","DOI":"10.62347\/ZIAX8828","volume":"14","author":"SL Lian","year":"2024","unstructured":"Lian SL, Lu YT, Lu YJ, Yao YL, Wang XL, Jiang RQ. Tumor-associated macrophages promoting PD-L1 expression in infiltrating B cells through the CXCL12\/CXCR4 axis in human hepatocellular carcinoma. Am J Cancer Res. 2024;14(2):832\u201353.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"3490_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/j.gastro.2024.02.025","volume":"167","author":"J Chen","year":"2024","unstructured":"Chen J, Feng W, Sun M, Huang W, Wang G, Chen X, Yin Y, Chen X, Zhang B, Nie Y, et al. TGF-beta1-Induced SOX18 elevation promotes hepatocellular carcinoma progression and metastasis through transcriptionally upregulating PD-L1 and CXCL12. Gastroenterology. 2024;167(2):264\u201380.","journal-title":"Gastroenterology"},{"issue":"40","key":"3490_CR24","doi-asserted-by":"publisher","first-page":"44407","DOI":"10.1021\/acsami.0c08473","volume":"12","author":"CC Chang","year":"2020","unstructured":"Chang CC, Dinh TK, Lee YA, Wang FN, Sung YC, Yu PL, Chiu SC, Shih YC, Wu CY, Huang YD, et al. Nanoparticle delivery of MnO(2) and antiangiogenic therapy to overcome Hypoxia-Driven tumor escape and suppress hepatocellular carcinoma. ACS Appl Mater Interfaces. 2020;12(40):44407\u201319.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3490_CR25","doi-asserted-by":"publisher","first-page":"1070961","DOI":"10.3389\/fimmu.2022.1070961","volume":"13","author":"Q Li","year":"2022","unstructured":"Li Q, Han J, Yang Y, Chen Y. PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol. 2022;13:1070961.","journal-title":"Front Immunol"},{"issue":"11","key":"3490_CR26","doi-asserted-by":"publisher","first-page":"OF3","DOI":"10.1158\/2159-8290.CD-NB2017-138","volume":"7","author":"Nivolumab Approved for Liver Cancer","year":"2017","unstructured":"Nivolumab Approved for Liver Cancer. Cancer Discov. 2017;7(11):OF3.","journal-title":"Cancer Discov"},{"issue":"7","key":"3490_CR27","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940\u201352.","journal-title":"Lancet Oncol"},{"issue":"7","key":"3490_CR28","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","volume":"27","author":"SJ Casak","year":"2021","unstructured":"Casak SJ, Donoghue M, Fashoyin-Aje L, Jiang X, Rodriguez L, Shen YL, Xu Y, Jiang X, Liu J, Zhao H, et al. FDA approval summary: Atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma. Clin Cancer Res. 2021;27(7):1836\u201341.","journal-title":"Clin Cancer Res"},{"key":"3490_CR29","doi-asserted-by":"crossref","unstructured":"Lau G, Abou-Alfa GK, Cheng AL, Sukeepaisarnjaroen W, Van Dao T, Kang YK, Thungappa SC, Kudo M, Sangro B, Kelley RK et al. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. J Hepatol 2024.","DOI":"10.1016\/j.jhep.2024.07.017"},{"issue":"5","key":"3490_CR30","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1159\/000537915","volume":"13","author":"F Rossari","year":"2024","unstructured":"Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, et al. Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with Atezolizumab plus bevacizumab: A Real-World, multicenter study. Liver Cancer. 2024;13(5):522\u201336.","journal-title":"Liver Cancer"},{"issue":"1","key":"3490_CR31","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","volume":"40","author":"H Zhang","year":"2021","unstructured":"Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, Zeng WJ, Liu Z, Cheng Q. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 2021;40(1):184.","journal-title":"J Exp Clin Cancer Res"},{"key":"3490_CR32","doi-asserted-by":"publisher","first-page":"106221","DOI":"10.1016\/j.intimp.2020.106221","volume":"80","author":"A Hosseini","year":"2020","unstructured":"Hosseini A, Gharibi T, Marofi F, Babaloo Z, Baradaran B. CTLA-4: from mechanism to autoimmune therapy. Int Immunopharmacol. 2020;80:106221.","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"3490_CR33","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/onco.13819","volume":"26","author":"MT Saung","year":"2021","unstructured":"Saung MT, Pelosof L, Casak S, Donoghue M, Lemery S, Yuan M, Rodriguez L, Schotland P, Chuk M, Davis G, et al. FDA approval summary: nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with Sorafenib. Oncologist. 2021;26(9):797\u2013806.","journal-title":"Oncologist"},{"key":"3490_CR34","doi-asserted-by":"publisher","first-page":"1238667","DOI":"10.3389\/fimmu.2023.1238667","volume":"14","author":"Q Qiao","year":"2023","unstructured":"Qiao Q, Han C, Ye S, Li J, Shao G, Bai Y, Xu A, Sun M, Wang W, Wu J, et al. The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase ib\/ii single-arm clinical trial. Front Immunol. 2023;14:1238667.","journal-title":"Front Immunol"},{"issue":"10","key":"3490_CR35","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","volume":"24","author":"X Gao","year":"2023","unstructured":"Gao X, Xu N, Li Z, Shen L, Ji K, Zheng Z, Liu D, Lou H, Bai L, Liu T, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial. Lancet Oncol. 2023;24(10):1134\u201346.","journal-title":"Lancet Oncol"},{"issue":"6","key":"3490_CR36","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s00262-025-04038-8","volume":"74","author":"Y Wang","year":"2025","unstructured":"Wang Y, Pan S, Tian J, Wang J, Yu Y, Wang S, Li F, Yang L, Liu X, Shen Y, et al. Cadonilimab, a PD-1\/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study. Cancer Immunol Immunother. 2025;74(6):186.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"3490_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41422-020-0277-x","volume":"30","author":"A Schnell","year":"2020","unstructured":"Schnell A, Bod L, Madi A, Kuchroo VK. The Yin and Yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. Cell Res. 2020;30(4):285\u201399.","journal-title":"Cell Res"},{"key":"3490_CR38","doi-asserted-by":"publisher","first-page":"101794","DOI":"10.1016\/j.tranon.2023.101794","volume":"38","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Li ZZ, Zhong NN, Cao LM, Liu B, Bu LL. Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care. Transl Oncol. 2023;38:101794.","journal-title":"Transl Oncol"},{"issue":"1","key":"3490_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3490_CR40","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13045-024-01651-5","volume":"17","author":"C Mao","year":"2024","unstructured":"Mao C, Xiong A, Qian J, Wang W, Liu Y, Zhang T, Wu Z, Ni H, Lu J, Long S, et al. Dual Inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase ia\/ib study. J Hematol Oncol. 2024;17(1):132.","journal-title":"J Hematol Oncol"},{"issue":"13","key":"3490_CR41","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","volume":"27","author":"G Curigliano","year":"2021","unstructured":"Curigliano G, Gelderblom H, Mach N, Doi T, Tai D, Forde PM, Sarantopoulos J, Bedard PL, Lin CC, Hodi FS, et al. Phase i\/ib clinical trial of sabatolimab, an Anti-TIM-3 antibody, alone and in combination with spartalizumab, an Anti-PD-1 antibody, in advanced solid tumors. Clin Cancer Res. 2021;27(13):3620\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3490_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40364-023-00543-z","volume":"12","author":"P Zhang","year":"2024","unstructured":"Zhang P, Liu X, Gu Z, Jiang Z, Zhao S, Song Y, Yu J. Targeting TIGIT for cancer immunotherapy: recent advances and future directions. Biomark Res. 2024;12(1):7.","journal-title":"Biomark Res"},{"issue":"13","key":"3490_CR43","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.2174\/0929867330666230324152532","volume":"31","author":"Y Mu","year":"2024","unstructured":"Mu Y, Guan X. CD155-TIGIT axis as a therapeutic target for cancer immunotherapy. Curr Med Chem. 2024;31(13):1634\u201345.","journal-title":"Curr Med Chem"},{"issue":"1","key":"3490_CR44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12943-023-01800-3","volume":"22","author":"X Chu","year":"2023","unstructured":"Chu X, Tian W, Wang Z, Zhang J, Zhou R. Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials. Mol Cancer. 2023;22(1):93.","journal-title":"Mol Cancer"},{"issue":"2","key":"3490_CR45","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/cei.13415","volume":"200","author":"MA ElTanbouly","year":"2020","unstructured":"ElTanbouly MA, Schaafsma E, Noelle RJ, Lines JL. VISTA: coming of age as a multi-lineage immune checkpoint. Clin Exp Immunol. 2020;200(2):120\u201330.","journal-title":"Clin Exp Immunol"},{"issue":"Suppl 3","key":"3490_CR46","first-page":"e000683","volume":"4","author":"M Tagliamento","year":"2020","unstructured":"Tagliamento M, Bironzo P, Novello S. New emerging targets in cancer immunotherapy: the role of VISTA. ESMO Open. 2020;4(Suppl 3):e000683.","journal-title":"ESMO Open"},{"issue":"Pt 2","key":"3490_CR47","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.semcancer.2021.08.008","volume":"86","author":"E Im","year":"2022","unstructured":"Im E, Sim DY, Lee HJ, Park JE, Park WY, Ko S, Kim B, Shim BS, Kim SH. Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy. Semin Cancer Biol. 2022;86(Pt 2):1066\u201375.","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"3490_CR48","first-page":"4315","volume":"19","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Liao N, Wu Y, Gao J, Li Z, Liu W, Wang Y, Li M, Li X, Chen L, et al. High expression of B7\u2013H2 or B7\u2013H3 is associated with poor prognosis in hepatocellular carcinoma. Mol Med Rep. 2019;19(5):4315\u201325.","journal-title":"Mol Med Rep"},{"key":"3490_CR49","doi-asserted-by":"crossref","unstructured":"Aggarwal C, Prawira A, Antonia S, Rahma O, Tolcher A, Cohen RB, Lou Y, Hauke R, Vogelzang N, D PZ.: Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial. J Immunother Cancer 2022, 10(4).","DOI":"10.1136\/jitc-2021-004424"},{"issue":"5","key":"3490_CR50","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1159\/000537966","volume":"13","author":"RS Finn","year":"2024","unstructured":"Finn RS, Kudo M, Barnes G, Meyer T, Boisserie F, Abdrashitov R, Chen Y, Li S, Zhu AX, Qin S, et al. Tislelizumab versus Sorafenib in First-Line treatment of unresectable hepatocellular carcinoma: impact on Health-Related quality of life in RATIONALE-301 study. Liver Cancer. 2024;13(5):548\u201360.","journal-title":"Liver Cancer"},{"issue":"4","key":"3490_CR51","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/13543784.2022.2022121","volume":"31","author":"B Xu","year":"2022","unstructured":"Xu B, Sun HC. Camrelizumab: an investigational agent for hepatocellular carcinoma. Expert Opin Investig Drugs. 2022;31(4):337\u201346.","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"3490_CR52","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus Sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22(7):977\u201390.","journal-title":"Lancet Oncol"},{"issue":"14","key":"3490_CR53","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1158\/1078-0432.CCR-24-0006","volume":"30","author":"Y Chen","year":"2024","unstructured":"Chen Y, Du C, Shen S, Zhang W, Shan Y, Lyu A, Wu J, Shang C, Luo X, Wei J, et al. Toripalimab plus bevacizumab as First-line treatment for advanced hepatocellular carcinoma: A prospective, multicenter, Single-Arm, phase II trial. Clin Cancer Res. 2024;30(14):2937\u201344.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"3490_CR54","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1002\/cncr.35226","volume":"130","author":"S Bishnoi","year":"2024","unstructured":"Bishnoi S, Kotasek D, Aghmesheh M, Yau T, Cosman R, Prawira A, Moore M, Chan SL, Mant A, Eek R, et al. Dual CTLA-4 and PD-1 checkpoint Blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study. Cancer. 2024;130(11):1991\u20132002.","journal-title":"Cancer"},{"issue":"1","key":"3490_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s44342-024-00033-0","volume":"23","author":"M Shah","year":"2025","unstructured":"Shah M, Hussain M, Woo HG. Structural insights into antibody-based immunotherapy for hepatocellular carcinoma. Genomics Inf. 2025;23(1):1.","journal-title":"Genomics Inf"},{"issue":"3","key":"3490_CR56","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","volume":"7","author":"TU Marron","year":"2022","unstructured":"Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, et al. Neoadjuvant Cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):219\u201329.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"3490_CR57","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13046-022-02383-5","volume":"41","author":"SL Chan","year":"2022","unstructured":"Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, Lin CC, Okusaka T, Weiss KH, Macarulla T, et al. A first-in-human phase 1\/2 study of FGF401 and combination of FGF401 with Spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. J Exp Clin Cancer Res. 2022;41(1):189.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"3490_CR58","doi-asserted-by":"publisher","first-page":"101021","DOI":"10.1016\/j.jhepr.2024.101021","volume":"6","author":"A Santoro","year":"2024","unstructured":"Santoro A, Assenat E, Yau T, Delord JP, Maur M, Knox J, Cattan S, Lee KH, Del Conte G, Springfeld C, et al. A phase ib\/ii trial of Capmatinib plus Spartalizumab vs. Spartalizumab alone in patients with pretreated hepatocellular carcinoma. JHEP Rep. 2024;6(4):101021.","journal-title":"JHEP Rep"},{"issue":"6","key":"3490_CR59","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(25)00190-1","volume":"26","author":"J Zhou","year":"2025","unstructured":"Zhou J, Bai L, Luo J, Bai Y, Pan Y, Yang X, Gao Y, Shi R, Zhang W, Zheng J, et al. Anlotinib plus penpulimab versus Sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial. Lancet Oncol. 2025;26(6):719\u201331.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3490_CR60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00262-024-03917-w","volume":"74","author":"Z Ren","year":"2025","unstructured":"Ren Z, Shao G, Shen J, Zhang L, Zhu X, Fang W, Sun G, Bai Y, Wu J, Liu L, et al. Phase 2 study of Serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma. Cancer Immunol Immunother. 2025;74(2):69.","journal-title":"Cancer Immunol Immunother"},{"issue":"15","key":"3490_CR61","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s40265-022-01787-z","volume":"82","author":"S Dhillon","year":"2022","unstructured":"Dhillon S. Pucotenlimab: first approval. Drugs. 2022;82(15):1557\u201364.","journal-title":"Drugs"},{"issue":"3","key":"3490_CR62","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000514420","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y, et al. Avelumab in combination with axitinib as First-Line treatment in patients with advanced hepatocellular carcinoma: results from the phase 1b VEGF liver 100 trial. Liver Cancer. 2021;10(3):249\u201359.","journal-title":"Liver Cancer"},{"issue":"8","key":"3490_CR63","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s00262-021-03102-3","volume":"71","author":"J Gong","year":"2022","unstructured":"Gong J, Cao J, Zhang Q, Xu N, Zhao Y, Xing B, Miao Z, Wu Y, Pan H, Gao Q, et al. Safety, antitumor activity and biomarkers of Sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial. Cancer Immunol Immunother. 2022;71(8):1897\u2013908.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"3490_CR64","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10637-025-01506-x","volume":"43","author":"L Ma","year":"2025","unstructured":"Ma L, Zhang Y, Fang Y, Hao C, Fan Q, Jiang D, Lu L, Su F, Yang C, Liu Z, et al. Anti-PD-L1 Envafolimab combined with anti-VEGF Suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage. Invest New Drugs. 2025;43(2):181\u201390.","journal-title":"Invest New Drugs"},{"issue":"1","key":"3490_CR65","first-page":"18","volume":"43","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Su K, Li H, Wang C, Wu Z, Chen J, Zhang Z, He K, Han Y. Efficacy and safety of the combination of Envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study. Invest New Drugs. 2025;43(1):18\u201329.","journal-title":"Invest New Drugs"},{"issue":"1","key":"3490_CR66","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41392-024-01991-1","volume":"9","author":"Y Chen","year":"2024","unstructured":"Chen Y, Zhang J, Hu W, Li X, Sun K, Shen Y, Zhang M, Wu J, Gao S, Yu J, et al. Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study. Signal Transduct Target Ther. 2024;9(1):280.","journal-title":"Signal Transduct Target Ther"},{"issue":"16suppl","key":"3490_CR67","doi-asserted-by":"publisher","first-page":"e16175","DOI":"10.1200\/JCO.2024.42.16_suppl.e16175","volume":"42","author":"B Chen","year":"2024","unstructured":"Chen B, Lin R, Huang Y, Dai H, Tang K, Zhang G. The safety and efficacy of adebelimumab combined apatinib and hepatic artery infusion chemotherapy in the treatment of unresectable hepatocellular carcinoma: A retrospective study. J Clin Oncol. 2024;42(16_suppl):e16175\u201316175.","journal-title":"J Clin Oncol"},{"issue":"18","key":"3490_CR68","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1002\/cncr.35377","volume":"130","author":"T Ning","year":"2024","unstructured":"Ning T, Li D, Deng T, Bai Y, Chen Y, Wang Z, Hu B, Ba Y, Lu W. Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study. Cancer. 2024;130(18):3137\u201346.","journal-title":"Cancer"},{"issue":"23","key":"3490_CR69","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1200\/JCO.23.01462","volume":"42","author":"B Sangro","year":"2024","unstructured":"Sangro B, Galle PR, Kelley RK, Charoentum C, De Toni EN, Ostapenko Y, Heo J, Cheng AL, Wilson Woods A, Gupta C, et al. Patient-Reported outcomes from the phase III HIMALAYA study of Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2024;42(23):2790\u20139.","journal-title":"J Clin Oncol"},{"issue":"20","key":"3490_CR70","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.4155\/fmc-2022-0045","volume":"14","author":"R Carloni","year":"2022","unstructured":"Carloni R, Rizzo A, Cusmai A, Palloni A, Federico AD, Marco MD, Massafra R, Fanizzi A, Palmiotti G, Brandi G. Advances in novel systemic therapies for advanced hepatocellular carcinoma. Future Med Chem. 2022;14(20):1455\u201370.","journal-title":"Future Med Chem"},{"issue":"28","key":"3490_CR71","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1080\/14796694.2024.2355863","volume":"20","author":"S Badhrinarayanan","year":"2024","unstructured":"Badhrinarayanan S, Cotter C, Zhu H, Lin YC, Kudo M, Li D. IMbrave152\/SKYSCRAPER-14: a phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma. Future Oncol. 2024;20(28):2049\u201357.","journal-title":"Future Oncol"},{"issue":"1","key":"3490_CR72","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","volume":"9","author":"A Bartolomucci","year":"2025","unstructured":"Bartolomucci A, Nobrega M, Ferrier T, Dickinson K, Kaorey N, Nadeau A, Castillo A, Burnier JV. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis Oncol. 2025;9(1):84.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"3490_CR73","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s43556-025-00257-8","volume":"6","author":"H Yin","year":"2025","unstructured":"Yin H, Zhang M, Zhang Y, Zhang X, Zhang X, Zhang B. Liquid biopsies in cancer. Mol Biomed. 2025;6(1):18.","journal-title":"Mol Biomed"},{"key":"3490_CR74","doi-asserted-by":"publisher","first-page":"1303335","DOI":"10.3389\/fonc.2024.1303335","volume":"14","author":"X Wang","year":"2024","unstructured":"Wang X, Wang L, Lin H, Zhu Y, Huang D, Lai M, Xi X, Huang J, Zhang W, Zhong T. Research progress of CTC, ctdna, and EVs in cancer liquid biopsy. Front Oncol. 2024;14:1303335.","journal-title":"Front Oncol"},{"key":"3490_CR75","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cytogfr.2024.08.006","volume":"79","author":"B Yu","year":"2024","unstructured":"Yu B, Ma W. Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis. Cytokine Growth Factor Rev. 2024;79:29\u201338.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"3","key":"3490_CR76","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1053\/j.seminoncol.2021.06.002","volume":"48","author":"A Mohanty","year":"2021","unstructured":"Mohanty A, Mohanty SK, Rout S, Pani C. Liquid biopsy, the hype vs. hope in molecular and clinical oncology. Semin Oncol. 2021;48(3):259\u201367.","journal-title":"Semin Oncol"},{"key":"3490_CR77","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2019.04.014","volume":"116","author":"J Howell","year":"2019","unstructured":"Howell J, Atkinson SR, Pinato DJ, Knapp S, Ward C, Minisini R, Burlone ME, Leutner M, Pirisi M, Buttner R, et al. Identification of mutations in Circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Eur J Cancer. 2019;116:56\u201366.","journal-title":"Eur J Cancer"},{"issue":"9","key":"3490_CR78","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-17-1753","volume":"24","author":"W Guo","year":"2018","unstructured":"Guo W, Sun YF, Shen MN, Ma XL, Wu J, Zhang CY, Zhou Y, Xu Y, Hu B, Zhang M, et al. Circulating tumor cells with Stem-Like phenotypes for diagnosis, prognosis, and therapeutic response evaluation in hepatocellular carcinoma. Clin Cancer Res. 2018;24(9):2203\u201313.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"3490_CR79","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","volume":"24","author":"R Raja","year":"2018","unstructured":"Raja R, Kuziora M, Brohawn PZ, Higgs BW, Gupta A, Dennis PA, Ranade K. Early reduction in ctdna predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin Cancer Res. 2018;24(24):6212\u201322.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3490_CR80","doi-asserted-by":"publisher","first-page":"1738798","DOI":"10.1080\/2162402X.2020.1738798","volume":"9","author":"S Bergmann","year":"2020","unstructured":"Bergmann S, Coym A, Ott L, Soave A, Rink M, Janning M, Stoupiec M, Coith C, Peine S, von Amsberg G, et al. Evaluation of PD-L1 expression on Circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). Oncoimmunology. 2020;9(1):1738798.","journal-title":"Oncoimmunology"},{"issue":"8","key":"3490_CR81","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","volume":"24","author":"SB Goldberg","year":"2018","unstructured":"Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM, et al. Early assessment of lung cancer immunotherapy response via Circulating tumor DNA. Clin Cancer Res. 2018;24(8):1872\u201380.","journal-title":"Clin Cancer Res"},{"key":"3490_CR82","doi-asserted-by":"crossref","unstructured":"Vargas-Accarino E, Higuera M, Bermudez-Ramos M, Soriano-Varela A, Torrens M, Pons M, Aransay AM, Martin JE, Rodriguez-Frias F, Merino X et al. Harnessing plasma biomarkers to predict immunotherapy outcomes in hepatocellular carcinoma: the role of cfdna, ctdna, and cytokines. Int J Mol Sci 2025, 26(6).","DOI":"10.3390\/ijms26062794"},{"key":"3490_CR83","doi-asserted-by":"crossref","unstructured":"Matsumae T, Kodama T, Myojin Y, Maesaka K, Sakamori R, Takuwa A, Oku K, Motooka D, Sawai Y, Oshita M et al. Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy. Cancers (Basel). 2022, 14(14).","DOI":"10.3390\/cancers14143367"},{"issue":"1","key":"3490_CR84","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s13046-021-02016-3","volume":"40","author":"Y Fujii","year":"2021","unstructured":"Fujii Y, Ono A, Hayes CN, Aikata H, Yamauchi M, Uchikawa S, Kodama K, Teraoka Y, Fujino H, Nakahara T, et al. Identification and monitoring of mutations in Circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. J Exp Clin Cancer Res. 2021;40(1):215.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"3490_CR85","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","volume":"25","author":"JJ Harding","year":"2019","unstructured":"Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of Next-Generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 2019;25(7):2116\u201326.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3490_CR86","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","volume":"9","author":"M Ruiz de Galarreta","year":"2019","unstructured":"Ruiz de Galarreta M, Bresnahan E, Molina-Sanchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, et al. beta-Catenin activation promotes immune escape and resistance to Anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9(8):1124\u201341.","journal-title":"Cancer Discov"},{"issue":"1","key":"3490_CR87","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12885-021-08103-0","volume":"21","author":"SK Oversoe","year":"2021","unstructured":"Oversoe SK, Clement MS, Weber B, Gronbaek H, Hamilton-Dutoit SJ, Sorensen BS, Kelsen J. Combining tissue and Circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. BMC Cancer. 2021;21(1):376.","journal-title":"BMC Cancer"},{"issue":"1","key":"3490_CR88","doi-asserted-by":"publisher","first-page":"188463","DOI":"10.1016\/j.bbcan.2020.188463","volume":"1875","author":"M Del Re","year":"2021","unstructured":"Del Re M, van Schaik RHN, Fogli S, Mathijssen RHJ, Cucchiara F, Capuano A, Scavone C, Jenster GW, Danesi R. Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: applications for optimal use of anti-PD-1\/PD-L1 axis inhibitors. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188463.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"5","key":"3490_CR89","doi-asserted-by":"publisher","first-page":"101047","DOI":"10.1016\/j.tranon.2021.101047","volume":"14","author":"J Wang","year":"2021","unstructured":"Wang J, Zeng H, Zhang H, Han Y. The role of Exosomal PD-L1 in tumor immunotherapy. Transl Oncol. 2021;14(5):101047.","journal-title":"Transl Oncol"},{"issue":"2","key":"3490_CR90","doi-asserted-by":"publisher","first-page":"100982","DOI":"10.1016\/j.jhepr.2023.100982","volume":"6","author":"L Balcar","year":"2024","unstructured":"Balcar L, Scheiner B, Fulgenzi CAM, D\u2019Alessio A, Pomej K, Roig MB, Meyer EL, Che J, Nishida N, Lee PC, et al. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma. JHEP Rep. 2024;6(2):100982.","journal-title":"JHEP Rep"},{"key":"3490_CR91","doi-asserted-by":"crossref","unstructured":"Wong JSL, Kwok GGW, Tang V, Li BCW, Leung R, Chiu J, Ma KW, She WH, Tsang J, Lo CM et al. Ipilimumab and nivolumab\/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. J Immunother Cancer 2021, 9(2).","DOI":"10.1136\/jitc-2020-001945"},{"issue":"11","key":"3490_CR92","doi-asserted-by":"publisher","first-page":"9789","DOI":"10.3390\/curroncol30110711","volume":"30","author":"F Bicer","year":"2023","unstructured":"Bicer F, Kure C, Ozluk AA, El-Rayes BF, Akce M. Advances in immunotherapy for hepatocellular carcinoma (HCC). Curr Oncol. 2023;30(11):9789\u2013812.","journal-title":"Curr Oncol"},{"issue":"1","key":"3490_CR93","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","volume":"24","author":"BH Alsaafeen","year":"2025","unstructured":"Alsaafeen BH, Ali BR, Elkord E. Resistance mechanisms to immune checkpoint inhibitors: updated insights. Mol Cancer. 2025;24(1):20.","journal-title":"Mol Cancer"},{"key":"3490_CR94","doi-asserted-by":"crossref","unstructured":"Zgura A, Chipuc S, Bacalbasa N, Haineala B, Rodica A, Sebastian V. Evaluating tumour mutational burden as a key biomarker in personalized cancer immunotherapy: A Pan-Cancer systematic review. Cancers (Basel) 2025, 17(3).","DOI":"10.3390\/cancers17030480"},{"issue":"2","key":"3490_CR95","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40259-024-00700-2","volume":"39","author":"A Mariniello","year":"2025","unstructured":"Mariniello A, Borgeaud M, Weiner M, Frisone D, Kim F, Addeo A. Primary and acquired resistance to immunotherapy with checkpoint inhibitors in NSCLC: from bedside to bench and back. BioDrugs. 2025;39(2):215\u201335.","journal-title":"BioDrugs"},{"key":"3490_CR96","doi-asserted-by":"publisher","first-page":"1233376","DOI":"10.3389\/fonc.2023.1233376","volume":"13","author":"J Lee","year":"2023","unstructured":"Lee J, Kim EH. Mechanisms underlying response and resistance to immune checkpoint Blockade in cancer immunotherapy. Front Oncol. 2023;13:1233376.","journal-title":"Front Oncol"},{"key":"3490_CR97","doi-asserted-by":"publisher","first-page":"693609","DOI":"10.3389\/fimmu.2021.693609","volume":"12","author":"B Zhou","year":"2021","unstructured":"Zhou B, Gao Y, Zhang P, Chu Q. Acquired resistance to immune checkpoint blockades: the underlying mechanisms and potential strategies. Front Immunol. 2021;12:693609.","journal-title":"Front Immunol"},{"key":"3490_CR98","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2019.07.017","volume":"65","author":"R Saleh","year":"2020","unstructured":"Saleh R, Elkord E. Acquired resistance to cancer immunotherapy: role of tumor-mediated immunosuppression. Semin Cancer Biol. 2020;65:13\u201327.","journal-title":"Semin Cancer Biol"},{"key":"3490_CR99","doi-asserted-by":"publisher","first-page":"1133308","DOI":"10.3389\/fimmu.2023.1133308","volume":"14","author":"C Chen","year":"2023","unstructured":"Chen C, Wang Z, Ding Y, Qin Y. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front Immunol. 2023;14:1133308.","journal-title":"Front Immunol"},{"key":"3490_CR100","doi-asserted-by":"crossref","unstructured":"Nishina S, Hino K. CD26\/DPP4 as a therapeutic target in nonalcoholic steatohepatitis associated hepatocellular carcinoma. Cancers (Basel) 2022, 14(2).","DOI":"10.3390\/cancers14020454"},{"issue":"6","key":"3490_CR101","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.pathol.2019.06.001","volume":"51","author":"GM Wiedemann","year":"2019","unstructured":"Wiedemann GM, Rohrle N, Makeschin MC, Fesseler J, Endres S, Mayr D, Anz D. Peritumoural CCL1 and CCL22 expressing cells in hepatocellular carcinomas shape the tumour immune infiltrate. Pathology. 2019;51(6):586\u201392.","journal-title":"Pathology"},{"issue":"1","key":"3490_CR102","doi-asserted-by":"publisher","first-page":"18848","DOI":"10.1038\/s41598-020-75881-1","volume":"10","author":"D Bayik","year":"2020","unstructured":"Bayik D, Lauko AJ, Roversi GA, Serbinowski E, Acevedo-Moreno LA, Lanigan C, Orujov M, Lo A, Alban TJ, Kim A, et al. Hepatobiliary malignancies have distinct peripheral myeloid-derived suppressor cell signatures and tumor myeloid cell profiles. Sci Rep. 2020;10(1):18848.","journal-title":"Sci Rep"},{"issue":"8","key":"3490_CR103","doi-asserted-by":"publisher","first-page":"167493","DOI":"10.1016\/j.bbadis.2024.167493","volume":"1870","author":"QQ Liu","year":"2024","unstructured":"Liu QQ, Li HZ, Li SX, Bao Y, Wang TC, Hu C, Xiao YD. CD36-mediated accumulation of MDSCs exerts abscopal immunosuppressive responses in hepatocellular carcinoma after insufficient microwave ablation. Biochim Biophys Acta Mol Basis Dis. 2024;1870(8):167493.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"3490_CR104","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00262-020-02660-2","volume":"70","author":"J Arai","year":"2021","unstructured":"Arai J, Goto K, Otoyama Y, Nakajima Y, Sugiura I, Kajiwara A, Tojo M, Ichikawa Y, Uozumi S, Shimozuma Y, et al. Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding. Cancer Immunol Immunother. 2021;70(1):203\u201313.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"3490_CR105","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.21873\/anticanres.16249","volume":"43","author":"K Ogawa","year":"2023","unstructured":"Ogawa K, Chiba T, Nakamura M, Arai J, Zhang J, Ma Y, Qiang NA, Ao J, Yumita S, Ishino T, et al. Successful identification of a novel therapeutic compound for hepatocellular carcinoma through screening of ADAM9 inhibitors. Anticancer Res. 2023;43(3):1043\u201352.","journal-title":"Anticancer Res"},{"key":"3490_CR106","doi-asserted-by":"crossref","unstructured":"Zeng W, Liu F, Liu Y, Zhang Z, Hu H, Ning S, Zhang H, Chen X, Liao Z, Zhang Z. Targeting TM4SF1 promotes tumor senescence enhancing CD8\u2009+\u2009T cell cytotoxic function in hepatocellular carcinoma. Clin Mol Hepatol 2024.","DOI":"10.3350\/cmh.2024.0934"},{"key":"3490_CR107","doi-asserted-by":"crossref","unstructured":"Morita M, Nishida N, Aoki T, Chishina H, Takita M, Ida H, Hagiwara S, Minami Y, Ueshima K, Kudo M. Role of beta-Catenin activation in the tumor immune microenvironment and immunotherapy of hepatocellular carcinoma. Cancers (Basel) 2023, 15(8).","DOI":"10.3390\/cancers15082311"},{"key":"3490_CR108","doi-asserted-by":"crossref","unstructured":"Huang M, Yang S, Tai WCS, Zhang L, Zhou Y, Cho WCS, Chan LWC, Wong SCC. Bioinformatics identification of regulatory genes and mechanism related to Hypoxia-Induced PD-L1 inhibitor resistance in hepatocellular carcinoma. Int J Mol Sci 2023, 24(10).","DOI":"10.3390\/ijms24108720"},{"issue":"11","key":"3490_CR109","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/cac2.12607","volume":"44","author":"J Cai","year":"2024","unstructured":"Cai J, Song L, Zhang F, Wu S, Zhu G, Zhang P, Chen S, Du J, Wang B, Cai Y, et al. Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma. Cancer Commun (Lond). 2024;44(11):1231\u201360.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"3490_CR110","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12943-025-02319-5","volume":"24","author":"L Fu","year":"2025","unstructured":"Fu L, Li S, Mei J, Li Z, Yang X, Zheng C, Li N, Lin Y, Cao C, Liu L, et al. BIRC2 Blockade facilitates immunotherapy of hepatocellular carcinoma. Mol Cancer. 2025;24(1):113.","journal-title":"Mol Cancer"},{"issue":"5","key":"3490_CR111","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/s41418-024-01437-9","volume":"32","author":"P Wang","year":"2025","unstructured":"Wang P, Qiu J, Fang Y, Li S, Liu K, Cao Y, Zhang G, Wang Z, Gu X, Wu J, et al. SENP3 Inhibition suppresses hepatocellular carcinoma progression and improves the efficacy of anti-PD-1 immunotherapy. Cell Death Differ. 2025;32(5):959\u201372.","journal-title":"Cell Death Differ"},{"issue":"6","key":"3490_CR112","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/hep.29360","volume":"66","author":"H Li","year":"2017","unstructured":"Li H, Li X, Liu S, Guo L, Zhang B, Zhang J, Ye Q. Programmed cell death-1 (PD-1) checkpoint Blockade in combination with a mammalian target of Rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. Hepatology. 2017;66(6):1920\u201333.","journal-title":"Hepatology"},{"key":"3490_CR113","doi-asserted-by":"crossref","unstructured":"Singer M, Zhang Z, Dayyani F, Zhang Z, Yaghmai V, Choi A, Valerin J, Imagawa D, Abi-Jaoudeh N. Modulation of Tumor-Associated macrophages to overcome immune suppression in the hepatocellular carcinoma microenvironment. Cancers (Basel) 2024, 17(1).","DOI":"10.3390\/cancers17010066"},{"issue":"1","key":"3490_CR114","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12943-024-02064-1","volume":"23","author":"X Chu","year":"2024","unstructured":"Chu X, Tian Y, Lv C. Decoding the Spatiotemporal heterogeneity of tumor-associated macrophages. Mol Cancer. 2024;23(1):150.","journal-title":"Mol Cancer"},{"key":"3490_CR115","doi-asserted-by":"publisher","first-page":"1558091","DOI":"10.3389\/fimmu.2025.1558091","volume":"16","author":"Y He","year":"2025","unstructured":"He Y, Hong Q, Chen S, Zhou J, Qiu S. Reprogramming tumor-associated macrophages in gastric cancer: a pathway to enhanced immunotherapy. Front Immunol. 2025;16:1558091.","journal-title":"Front Immunol"},{"key":"3490_CR116","doi-asserted-by":"publisher","first-page":"656364","DOI":"10.3389\/fimmu.2021.656364","volume":"12","author":"K Khalaf","year":"2021","unstructured":"Khalaf K, Hana D, Chou JT, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front Immunol. 2021;12:656364.","journal-title":"Front Immunol"},{"issue":"11","key":"3490_CR117","doi-asserted-by":"publisher","first-page":"e2408788","DOI":"10.1002\/advs.202408788","volume":"12","author":"X Yu","year":"2025","unstructured":"Yu X, Qian J, Ding L, Pan C, Liu X, Wu Q, Wang S, Liu J, Shang M, Su R, et al. Galectin-1-Induced tumor associated macrophages repress antitumor immunity in hepatocellular carcinoma through recruitment of Tregs. Adv Sci (Weinh). 2025;12(11):e2408788.","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"3490_CR118","doi-asserted-by":"publisher","first-page":"102000","DOI":"10.1016\/j.xcrm.2025.102000","volume":"6","author":"S Yang","year":"2025","unstructured":"Yang S, Qiu X, Yang Y, Wu J, Wang S, Zheng B, Wu J, Zhou T, Zhang Y, Bai M, et al. LTA4H improves the tumor microenvironment and prevents HCC progression via targeting the HNRNPA1\/LTBP1\/TGF-beta axis. Cell Rep Med. 2025;6(3):102000.","journal-title":"Cell Rep Med"},{"issue":"1","key":"3490_CR119","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41467-024-55577-0","volume":"16","author":"T Lan","year":"2025","unstructured":"Lan T, Gao F, Cai Y, Lv Y, Zhu J, Liu H, Xie S, Wan H, He H, Xie K, et al. The protein circPETH-147aa regulates metabolic reprogramming in hepatocellular carcinoma cells to remodel immunosuppressive microenvironment. Nat Commun. 2025;16(1):333.","journal-title":"Nat Commun"},{"key":"3490_CR120","doi-asserted-by":"crossref","unstructured":"Zhang F, Liu W, Meng F, Jiang Q, Tang W, Liu Z, Lin X, Xue R, Zhang S, Dong L. Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma. J Immunother Cancer 2024, 12(1).","DOI":"10.1136\/jitc-2023-008094"},{"issue":"5","key":"3490_CR121","doi-asserted-by":"publisher","first-page":"101505","DOI":"10.1016\/j.xcrm.2024.101505","volume":"5","author":"J Ning","year":"2024","unstructured":"Ning J, Ye Y, Shen H, Zhang R, Li H, Song T, Zhang R, Liu P, Chen G, Wang H, et al. Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation. Cell Rep Med. 2024;5(5):101505.","journal-title":"Cell Rep Med"},{"issue":"6","key":"3490_CR122","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ccell.2023.04.018","volume":"41","author":"X Liu","year":"2023","unstructured":"Liu X, Hogg GD, Zuo C, Borcherding NC, Baer JM, Lander VE, Kang LI, Knolhoff BL, Ahmad F, Osterhout RE, et al. Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity. Cancer Cell. 2023;41(6):1073\u201390. e1012.","journal-title":"Cancer Cell"},{"issue":"1","key":"3490_CR123","doi-asserted-by":"publisher","first-page":"101217","DOI":"10.1016\/j.jhepr.2024.101217","volume":"7","author":"J Li","year":"2025","unstructured":"Li J, Zhang C, Zhou Q, Long Q, Chen J, Meng L, Tian W, Yang Y, Ge C, Su Y, et al. ALDH1L2 drives HCC progression through TAM polarization. JHEP Rep. 2025;7(1):101217.","journal-title":"JHEP Rep"},{"key":"3490_CR124","unstructured":"Shi B, Du M, Chen Z. Advances in tumor immunotherapy targeting macrophages. Expert Rev Clin Immunol 2024:1\u201318."},{"issue":"2","key":"3490_CR125","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1021\/acs.jproteome.3c00725","volume":"23","author":"Y Liu","year":"2024","unstructured":"Liu Y, Liu D, Liu Y, Fu B, Ji S, Wang R, Yan F, Wang H, Zhao D, Yang W, et al. Comprehensive proteomics analysis reveals dynamic phenotypes of tumor-Associated macrophages and their precursor cells in tumor progression. J Proteome Res. 2024;23(2):822\u201333.","journal-title":"J Proteome Res"},{"issue":"6","key":"3490_CR126","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s10753-024-02026-1","volume":"47","author":"X Li","year":"2024","unstructured":"Li X, Li R, Miao X, Zhou X, Wu B, Cao J, Wang C, Li S, Cai J. Integrated single cell analysis reveals an atlas of tumor associated macrophages in hepatocellular carcinoma. Inflammation. 2024;47(6):2077\u201393.","journal-title":"Inflammation"},{"issue":"23","key":"3490_CR127","doi-asserted-by":"publisher","first-page":"e2007603","DOI":"10.1002\/adma.202007603","volume":"33","author":"Y Wang","year":"2021","unstructured":"Wang Y, Tiruthani K, Li S, Hu M, Zhong G, Tang Y, Roy S, Zhang L, Tan J, Liao C, et al. mRNA delivery of a bispecific Single-Domain antibody to polarize Tumor-Associated macrophages and synergize immunotherapy against liver malignancies. Adv Mater. 2021;33(23):e2007603.","journal-title":"Adv Mater"},{"issue":"11","key":"3490_CR128","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ccell.2023.09.014","volume":"41","author":"T Kerzel","year":"2023","unstructured":"Kerzel T, Giacca G, Beretta S, Bresesti C, Notaro M, Scotti GM, Balestrieri C, Canu T, Redegalli M, Pedica F, et al. In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases. Cancer Cell. 2023;41(11):1892\u2013910. e1810.","journal-title":"Cancer Cell"},{"issue":"12","key":"3490_CR129","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41423-024-01232-z","volume":"21","author":"J Kzhyshkowska","year":"2024","unstructured":"Kzhyshkowska J, Shen J, Larionova I. Targeting of tams: can we be more Clever than cancer cells? Cell Mol Immunol. 2024;21(12):1376\u2013409.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"3490_CR130","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.semcancer.2012.02.002","volume":"22","author":"A Schmieder","year":"2012","unstructured":"Schmieder A, Michel J, Schonhaar K, Goerdt S, Schledzewski K. Differentiation and gene expression profile of tumor-associated macrophages. Semin Cancer Biol. 2012;22(4):289\u201397.","journal-title":"Semin Cancer Biol"},{"key":"3490_CR131","doi-asserted-by":"crossref","unstructured":"Arora S, Singh P, Ahmad S, Ahmad T, Dohare R, Almatroodi SA, Alrumaihi F, Rahmani AH, Syed MA. Comprehensive integrative analysis reveals the association of KLF4 with macrophage infiltration and polarization in lung cancer microenvironment. Cells 2021, 10(8).","DOI":"10.3390\/cells10082091"},{"key":"3490_CR132","doi-asserted-by":"publisher","first-page":"644608","DOI":"10.3389\/fonc.2021.644608","volume":"11","author":"M Natoli","year":"2021","unstructured":"Natoli M, Herzig P, Pishali Bejestani E, Buchi M, Ritschard R, Lloyd GK, Mohanlal R, Tonra JR, Huang L, Heinzelmann V, et al. Plinabulin, a distinct Microtubule-Targeting chemotherapy, promotes M1-Like macrophage polarization and Anti-tumor immunity. Front Oncol. 2021;11:644608.","journal-title":"Front Oncol"},{"issue":"9","key":"3490_CR133","doi-asserted-by":"publisher","first-page":"6863","DOI":"10.1021\/acsnano.3c06987","volume":"18","author":"P Zheng","year":"2024","unstructured":"Zheng P, He J, Fu Y, Yang Y, Li S, Duan B, Yang Y, Hu Y, Yang Z, Wang M, et al. Engineered bacterial biomimetic vesicles reprogram tumor-Associated macrophages and remodel tumor microenvironment to promote innate and adaptive antitumor immune responses. ACS Nano. 2024;18(9):6863\u201386.","journal-title":"ACS Nano"},{"issue":"10","key":"3490_CR134","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"SK Biswas","year":"2010","unstructured":"Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889\u201396.","journal-title":"Nat Immunol"},{"issue":"11","key":"3490_CR135","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00109-021-02123-w","volume":"99","author":"A Salminen","year":"2021","unstructured":"Salminen A. Immunosuppressive network promotes Immunosenescence associated with aging and chronic inflammatory conditions. J Mol Med (Berl). 2021;99(11):1553\u201369.","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"3490_CR136","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1186\/s12885-024-12871-w","volume":"24","author":"B Deswal","year":"2024","unstructured":"Deswal B, Bagchi U, Santra MK, Garg M, Kapoor S. Inhibition of STAT3 by 2-Methoxyestradiol suppresses M2 polarization and protumoral functions of macrophages in breast cancer. BMC Cancer. 2024;24(1):1129.","journal-title":"BMC Cancer"},{"issue":"1","key":"3490_CR137","doi-asserted-by":"publisher","first-page":"13582","DOI":"10.1038\/s41598-020-70137-4","volume":"10","author":"DJ Shiau","year":"2020","unstructured":"Shiau DJ, Kuo WT, Davuluri GVN, Shieh CC, Tsai PJ, Chen CC, Lin YS, Wu YZ, Hsiao YP, Chang CP. Hepatocellular carcinoma-derived high mobility group box 1 triggers M2 macrophage polarization via a TLR2\/NOX2\/autophagy axis. Sci Rep. 2020;10(1):13582.","journal-title":"Sci Rep"},{"issue":"25","key":"3490_CR138","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1038\/s41388-019-0772-z","volume":"38","author":"D Bao","year":"2019","unstructured":"Bao D, Zhao J, Zhou X, Yang Q, Chen Y, Zhu J, Yuan P, Yang J, Qin T, Wan S, et al. Mitochondrial fission-induced MtDNA stress promotes tumor-associated macrophage infiltration and HCC progression. Oncogene. 2019;38(25):5007\u201320.","journal-title":"Oncogene"},{"issue":"9","key":"3490_CR139","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/s41418-023-01202-4","volume":"30","author":"S Tan","year":"2023","unstructured":"Tan S, Wang Z, Li N, Guo X, Zhang Y, Ma H, Peng X, Zhao Y, Li C, Gao L, et al. Transcription factor Zhx2 is a checkpoint that programs macrophage polarization and antitumor response. Cell Death Differ. 2023;30(9):2104\u201319.","journal-title":"Cell Death Differ"},{"issue":"2","key":"3490_CR140","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41419-018-0284-8","volume":"9","author":"M Li","year":"2018","unstructured":"Li M, Lai X, Zhao Y, Zhang Y, Li M, Li D, Kong J, Zhang Y, Jing P, Li H, et al. Loss of NDRG2 in liver microenvironment inhibits cancer liver metastasis by regulating tumor associate macrophages polarization. Cell Death Dis. 2018;9(2):248.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3490_CR141","doi-asserted-by":"publisher","first-page":"9128","DOI":"10.1038\/s41598-024-59725-w","volume":"14","author":"Q Wei","year":"2024","unstructured":"Wei Q, Luo S, He G. Mechanism study of tyrosine phosphatase shp-1 in inhibiting hepatocellular carcinoma progression by regulating the SHP2\/GM-CSF pathway in TAMs. Sci Rep. 2024;14(1):9128.","journal-title":"Sci Rep"},{"key":"3490_CR142","doi-asserted-by":"publisher","first-page":"111494","DOI":"10.1016\/j.intimp.2024.111494","volume":"128","author":"M Jiang","year":"2024","unstructured":"Jiang M, Wang D, Su N, Lou W, Chen Y, Yang H, Chen C, Xi F, Chen Y, Deng L, et al. TRIM65 knockout inhibits the development of HCC by polarization tumor-associated macrophages towards M1 phenotype via JAK1\/STAT1 signaling pathway. Int Immunopharmacol. 2024;128:111494.","journal-title":"Int Immunopharmacol"},{"key":"3490_CR143","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.molimm.2022.09.005","volume":"151","author":"F Chen","year":"2022","unstructured":"Chen F, Yang L, Peng X, Mao M, Liu X, Song J, Hu J. Histone deacetylase 2 regulates STAT1-dependent upregulation of atypical chemokine receptor 3 to induce M2 macrophage migration and immune escape in hepatocellular carcinoma. Mol Immunol. 2022;151:204\u201317.","journal-title":"Mol Immunol"},{"issue":"1","key":"3490_CR144","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/s13046-019-1456-9","volume":"38","author":"Z Li","year":"2019","unstructured":"Li Z, Li H, Zhao ZB, Zhu W, Feng PP, Zhu XW, Gong JP. SIRT4 Silencing in tumor-associated macrophages promotes HCC development via PPARdelta signalling-mediated alternative activation of macrophages. J Exp Clin Cancer Res. 2019;38(1):469.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3490_CR145","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3892\/or.2014.3587","volume":"33","author":"FB Kang","year":"2015","unstructured":"Kang FB, Wang L, Li D, Zhang YG, Sun DX. Hepatocellular carcinomas promote tumor-associated macrophage M2-polarization via increased B7-H3 expression. Oncol Rep. 2015;33(1):274\u201382.","journal-title":"Oncol Rep"},{"key":"3490_CR146","doi-asserted-by":"crossref","unstructured":"Okikawa S, Morine Y, Saito Y, Yamada S, Tokuda K, Teraoku H, Miyazaki K, Yamashita S, Ikemoto T, Imura S et al. Inhibition of the VEGF signaling pathway attenuates tumor\u2013associated macrophage activity in liver cancer. Oncol Rep 2022, 47(4).","DOI":"10.3892\/or.2022.8282"},{"issue":"8","key":"3490_CR147","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1158\/0008-5472.CAN-21-0003","volume":"82","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Bai F, Ren X, Sun R, Guo X, Liu W, Wang B, Yang Y, Zhang X, Xu Y, et al. Phosphoinositide-Binding protein TIPE1 promotes alternative activation of macrophages and tumor progression via PIP3\/Akt\/TGFbeta axis. Cancer Res. 2022;82(8):1603\u201316.","journal-title":"Cancer Res"},{"key":"3490_CR148","doi-asserted-by":"crossref","unstructured":"Chen M, Lai R, Lin X, Chen W, Wu H, Zheng Q. Downregulation of triggering receptor expressed on myeloid cells 1 inhibits invasion and migration of liver cancer cells by mediating macrophage polarization. Oncol Rep 2021, 45(4).","DOI":"10.3892\/or.2021.7988"},{"issue":"6","key":"3490_CR149","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/15384101.2024.2355825","volume":"23","author":"Y Yu","year":"2024","unstructured":"Yu Y, Nie G, Ren YW, Ouyang L, Ni CM. Pumilio RNA binding family member 1 deficiency activates anti-tumor immunity in hepatocellular carcinoma via restraining M2 macrophage polarization. Cell Cycle. 2024;23(6):682\u201392.","journal-title":"Cell Cycle"},{"issue":"4","key":"3490_CR150","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jhep.2024.05.007","volume":"81","author":"CX Zhu","year":"2024","unstructured":"Zhu CX, Yan K, Chen L, Huang RR, Bian ZH, Wei HR, Gu XM, Zhao YY, Liu MC, Suo CX, et al. Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8(+) T cells in hepatocellular carcinoma. J Hepatol. 2024;81(4):690\u2013703.","journal-title":"J Hepatol"},{"issue":"1","key":"3490_CR151","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12967-021-03034-7","volume":"19","author":"JL Sun","year":"2021","unstructured":"Sun JL, Zhang NP, Xu RC, Zhang GC, Liu ZY, Abuduwaili W, Wang F, Yu XN, Shi X, Song GQ, et al. Tumor cell-imposed iron restriction drives immunosuppressive polarization of tumor-associated macrophages. J Transl Med. 2021;19(1):347.","journal-title":"J Transl Med"},{"issue":"5","key":"3490_CR152","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1158\/2326-6066.CIR-19-0261","volume":"8","author":"L Wu","year":"2020","unstructured":"Wu L, Zhang X, Zheng L, Zhao H, Yan G, Zhang Q, Zhou Y, Lei J, Zhang J, Wang J, et al. RIPK3 orchestrates fatty acid metabolism in Tumor-Associated macrophages and hepatocarcinogenesis. Cancer Immunol Res. 2020;8(5):710\u201321.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"3490_CR153","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1080\/08820139.2022.2027439","volume":"51","author":"J Hu","year":"2022","unstructured":"Hu J, Zhang M, Gui L, Wan Q, Zhong J, Bai L, He M. PCSK9 suppresses M2-Like Tumor-Associated macrophage polarization by regulating the secretion of OX40L from hepatocellular carcinoma cells. Immunol Invest. 2022;51(6):1678\u201393.","journal-title":"Immunol Invest"},{"issue":"1","key":"3490_CR154","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12964-022-00872-w","volume":"21","author":"Y Lu","year":"2023","unstructured":"Lu Y, Han G, Zhang Y, Zhang L, Li Z, Wang Q, Chen Z, Wang X, Wu J. M2 macrophage-secreted exosomes promote metastasis and increase vascular permeability in hepatocellular carcinoma. Cell Commun Signal. 2023;21(1):299.","journal-title":"Cell Commun Signal"},{"key":"3490_CR155","doi-asserted-by":"crossref","unstructured":"Yu H, Pan J, Zheng S, Cai D, Luo A, Xia Z, Huang J. Hepatocellular carcinoma Cell-Derived Exosomal miR-21-5p induces macrophage M2 polarization by targeting RhoB. Int J Mol Sci 2023, 24(5).","DOI":"10.3390\/ijms24054593"},{"issue":"5","key":"3490_CR156","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/jvh.13809","volume":"30","author":"Y Fei","year":"2023","unstructured":"Fei Y, Wang Z, Huang M, Wu X, Hu F, Zhu J, Yu Y, Shen H, Wu Y, Xie G, et al. MiR-155 regulates M2 polarization of hepatitis B virus-infected tumour-associated macrophages which in turn regulates the malignant progression of hepatocellular carcinoma. J Viral Hepat. 2023;30(5):417\u201326.","journal-title":"J Viral Hepat"},{"key":"3490_CR1561","doi-asserted-by":"crossref","unstructured":"Zhao J, Li H, Zhao S, Wang E, Zhu J, Feng D, et al. Epigenetic silencing of miR-144\/451a cluster contributes to HCC progression via paracrine HGF\/MIF-mediated TAM remodeling. Mol Cancer. 2021;20(1):46. PMID: 33658044.","DOI":"10.1186\/s12943-021-01343-5"},{"issue":"12","key":"3490_CR157","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1172\/JCI128644","volume":"129","author":"AJ Petty","year":"2019","unstructured":"Petty AJ, Li A, Wang X, Dai R, Heyman B, Hsu D, Huang X, Yang Y. Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8\u2009+\u2009T cell recruitment. J Clin Invest. 2019;129(12):5151\u201362.","journal-title":"J Clin Invest"},{"issue":"6","key":"3490_CR158","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/iep.12374","volume":"101","author":"X Wang","year":"2020","unstructured":"Wang X, Li FY, Zhao W, Gao ZK, Shen B, Xu H, Cui YF. Long non-coding RNA GAS5 overexpression inhibits M2-like polarization of tumour-associated macrophages in SMCC-7721 cells by promoting PTEN expression. Int J Exp Pathol. 2020;101(6):215\u201322.","journal-title":"Int J Exp Pathol"},{"key":"3490_CR159","doi-asserted-by":"publisher","first-page":"112568","DOI":"10.1016\/j.intimp.2024.112568","volume":"138","author":"J Yang","year":"2024","unstructured":"Yang J, Wei W, Zhang S, Jiang W. Chronic stress influences the macrophage M1-M2 polarization balance through beta-adrenergic signaling in hepatoma mice. Int Immunopharmacol. 2024;138:112568.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"3490_CR160","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/kjm2.12651","volume":"39","author":"LF Yang","year":"2023","unstructured":"Yang LF, Zhang ZB, Wang L. S100A9 promotes tumor-associated macrophage for M2 macrophage polarization to drive human liver cancer progression: an in vitro study. Kaohsiung J Med Sci. 2023;39(4):345\u201353.","journal-title":"Kaohsiung J Med Sci"},{"issue":"2","key":"3490_CR161","doi-asserted-by":"publisher","first-page":"892","DOI":"10.7150\/thno.87962","volume":"14","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Tsui YM, Zhang VX, Lu AJ, Lee JM, Lee E, Cheung GC, Li PM, Cheung ET, Chia NH, et al. Reciprocal interactions between malignant cells and macrophages enhance cancer stemness and M2 polarization in HBV-associated hepatocellular carcinoma. Theranostics. 2024;14(2):892\u2013910.","journal-title":"Theranostics"},{"key":"3490_CR162","doi-asserted-by":"publisher","first-page":"7263358","DOI":"10.1155\/2024\/7263358","volume":"2024","author":"K Xu","year":"2024","unstructured":"Xu K, Dong M, Wu Z, Luo L, Xie F, Li F, Huang H, Wang F, Xiong X, Wen Z. Single-Cell RNA sequencing identifies crucial genes influencing the polarization of Tumor-Associated macrophages in liver cancer. Int J Genomics. 2024;2024:7263358.","journal-title":"Int J Genomics"},{"issue":"9","key":"3490_CR163","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/s41388-017-0048-4","volume":"37","author":"JB Yang","year":"2018","unstructured":"Yang JB, Zhao ZB, Liu QZ, Hu TD, Long J, Yan K, Lian ZX. FoxO1 is a regulator of MHC-II expression and anti-tumor effect of tumor-associated macrophages. Oncogene. 2018;37(9):1192\u2013204.","journal-title":"Oncogene"},{"issue":"8","key":"3490_CR164","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-16-0866","volume":"16","author":"JY Ao","year":"2017","unstructured":"Ao JY, Zhu XD, Chai ZT, Cai H, Zhang YY, Zhang KZ, Kong LQ, Zhang N, Ye BG, Ma DN, et al. Colony-Stimulating factor 1 receptor Blockade inhibits tumor growth by altering the polarization of tumor-Associated macrophages in hepatocellular carcinoma. Mol Cancer Ther. 2017;16(8):1544\u201354.","journal-title":"Mol Cancer Ther"},{"issue":"7938","key":"3490_CR165","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-022-05400-x","volume":"612","author":"R Xue","year":"2022","unstructured":"Xue R, Zhang Q, Cao Q, Kong R, Xiang X, Liu H, Feng M, Wang F, Cheng J, Li Z, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature. 2022;612(7938):141\u20137.","journal-title":"Nature"},{"issue":"7","key":"3490_CR166","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1053\/j.gastro.2016.02.040","volume":"150","author":"SL Zhou","year":"2016","unstructured":"Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, Fan J, Cao Y, Dai Z, Zhou J. Tumor-Associated neutrophils recruit macrophages and T-Regulatory cells to promote progression of hepatocellular carcinoma and resistance to Sorafenib. Gastroenterology. 2016;150(7):1646\u201358. e1617.","journal-title":"Gastroenterology"},{"issue":"1","key":"3490_CR167","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41392-025-02242-7","volume":"10","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Shen G, Zhou X, Li J. Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity. Signal Transduct Target Ther. 2025;10(1):178.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"3490_CR168","first-page":"421","volume":"20","author":"M Feng","year":"2023","unstructured":"Feng M, Wang F, Liu X, Hao T, Zhang N, Deng M, Pan Y, Kong R. Neutrophils as key regulators of tumor immunity that restrict immune checkpoint Blockade in liver cancer. Cancer Biol Med. 2023;20(6):421\u201337.","journal-title":"Cancer Biol Med"},{"issue":"7","key":"3490_CR169","doi-asserted-by":"publisher","first-page":"e1440166","DOI":"10.1080\/2162402X.2018.1440166","volume":"7","author":"P Xiao","year":"2018","unstructured":"Xiao P, Long X, Zhang L, Ye Y, Guo J, Liu P, Zhang R, Ning J, Yu W, Wei F, et al. Neurotensin\/IL-8 pathway orchestrates local inflammatory response and tumor invasion by inducing M2 polarization of Tumor-Associated macrophages and epithelial-mesenchymal transition of hepatocellular carcinoma cells. Oncoimmunology. 2018;7(7):e1440166.","journal-title":"Oncoimmunology"},{"issue":"23","key":"3490_CR170","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.3748\/wjg.v18.i23.2938","volume":"18","author":"J Yang","year":"2012","unstructured":"Yang J, Zhang JX, Wang H, Wang GL, Hu QG, Zheng QC. Hepatocellular carcinoma and macrophage interaction induced tumor immunosuppression via Treg requires TLR4 signaling. World J Gastroenterol. 2012;18(23):2938\u201347.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3490_CR171","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.30593","volume":"70","author":"Q Wu","year":"2019","unstructured":"Wu Q, Zhou W, Yin S, Zhou Y, Chen T, Qian J, Su R, Hong L, Lu H, Zhang F, et al. Blocking triggering receptor expressed on myeloid cells-1-Positive Tumor-Associated macrophages induced by hypoxia reverses immunosuppression and Anti-Programmed cell death ligand 1 resistance in liver cancer. Hepatology. 2019;70(1):198\u2013214.","journal-title":"Hepatology"},{"issue":"4","key":"3490_CR172","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41419-019-1435-2","volume":"10","author":"R Zhang","year":"2019","unstructured":"Zhang R, Qi F, Zhao F, Li G, Shao S, Zhang X, Yuan L, Feng Y. Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer. Cell Death Dis. 2019;10(4):273.","journal-title":"Cell Death Dis"},{"key":"3490_CR173","doi-asserted-by":"publisher","first-page":"1194642","DOI":"10.3389\/fimmu.2023.1194642","volume":"14","author":"E Timperi","year":"2023","unstructured":"Timperi E, Romano E. Stromal circuits involving tumor-associated macrophages and cancer-associated fibroblasts. Front Immunol. 2023;14:1194642.","journal-title":"Front Immunol"},{"issue":"8","key":"3490_CR174","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/onc.2016.273","volume":"36","author":"Y Deng","year":"2017","unstructured":"Deng Y, Cheng J, Fu B, Liu W, Chen G, Zhang Q, Yang Y. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells. Oncogene. 2017;36(8):1090\u2013101.","journal-title":"Oncogene"},{"issue":"9","key":"3490_CR175","doi-asserted-by":"publisher","first-page":"113067","DOI":"10.1016\/j.celrep.2023.113067","volume":"42","author":"CN Hung","year":"2023","unstructured":"Hung CN, Chen M, DeArmond DT, Chiu CH, Limboy CA, Tan X, Kusi M, Chou CW, Lin LL, Zhang Z, et al. AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages. Cell Rep. 2023;42(9):113067.","journal-title":"Cell Rep"},{"issue":"23","key":"3490_CR176","doi-asserted-by":"publisher","first-page":"5242","DOI":"10.1158\/1078-0432.CCR-24-1690","volume":"30","author":"E Timperi","year":"2024","unstructured":"Timperi E, Croizer H, Khantakova D, Rana M, Molgora M, Guerriero JL, Mechta-Grigoriou F, Romano E. At the interface of Tumor-Associated macrophages and fibroblasts: Immune-Suppressive networks and emerging exploitable targets. Clin Cancer Res. 2024;30(23):5242\u201351.","journal-title":"Clin Cancer Res"},{"key":"3490_CR177","doi-asserted-by":"publisher","first-page":"1194199","DOI":"10.3389\/fcell.2023.1194199","volume":"11","author":"J Gao","year":"2023","unstructured":"Gao J, Li Z, Lu Q, Zhong J, Pan L, Feng C, Tang S, Wang X, Tao Y, Lin J, et al. Single-cell RNA sequencing reveals cell subpopulations in the tumor microenvironment contributing to hepatocellular carcinoma. Front Cell Dev Biol. 2023;11:1194199.","journal-title":"Front Cell Dev Biol"},{"key":"3490_CR178","doi-asserted-by":"publisher","first-page":"216568","DOI":"10.1016\/j.canlet.2023.216568","volume":"582","author":"L Ding","year":"2024","unstructured":"Ding L, Qian J, Yu X, Wu Q, Mao J, Liu X, Wang Y, Guo D, Su R, Xie H, et al. Blocking MARCO(+) tumor-associated macrophages improves anti-PD-L1 therapy of hepatocellular carcinoma by promoting the activation of STING-IFN type I pathway. Cancer Lett. 2024;582:216568.","journal-title":"Cancer Lett"},{"issue":"11","key":"3490_CR179","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1158\/2326-6066.CIR-23-0627","volume":"12","author":"X Xiang","year":"2024","unstructured":"Xiang X, Wang K, Zhang H, Mou H, Shi Z, Tao Y, Song H, Lian Z, Wang S, Lu D, et al. Blocking CX3CR1\u2009+\u2009Tumor-Associated macrophages enhances the efficacy of Anti-PD1 therapy in hepatocellular carcinoma. Cancer Immunol Res. 2024;12(11):1603\u201320.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"3490_CR180","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1158\/0008-5472.CAN-24-0954","volume":"85","author":"P Xie","year":"2025","unstructured":"Xie P, Guo L, Yu Q, Zhao Y, Yu M, Wang H, Wu M, Xu W, Xu M, Zhu XD, et al. ACE2 enhances sensitivity to PD-L1 Blockade by inhibiting Macrophage-Induced immunosuppression and angiogenesis. Cancer Res. 2025;85(2):299\u2013313.","journal-title":"Cancer Res"},{"key":"3490_CR181","doi-asserted-by":"crossref","unstructured":"Liu S, Yang S, Xu M, Zhou Q, Weng J, Hu Z, Xu M, Xu W, Yi Y, Shi Y et al. WWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy. J Immunother Cancer 2024, 12(11).","DOI":"10.1136\/jitc-2024-010422"},{"issue":"1","key":"3490_CR182","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jhep.2022.02.019","volume":"77","author":"CY Wei","year":"2022","unstructured":"Wei CY, Zhu MX, Zhang PF, Huang XY, Wan JK, Yao XZ, Hu ZT, Chai XQ, Peng R, Yang X, et al. PKCalpha\/ZFP64\/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. J Hepatol. 2022;77(1):163\u201376.","journal-title":"J Hepatol"},{"issue":"4","key":"3490_CR183","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1158\/0008-5472.CAN-22-0232","volume":"83","author":"R Dhanasekaran","year":"2023","unstructured":"Dhanasekaran R, Hansen AS, Park J, Lemaitre L, Lai I, Adeniji N, Kuruvilla S, Suresh A, Zhang J, Swamy V, et al. MYC overexpression drives immune evasion in hepatocellular carcinoma that is reversible through restoration of Proinflammatory macrophages. Cancer Res. 2023;83(4):626\u201340.","journal-title":"Cancer Res"},{"issue":"12","key":"3490_CR184","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/s41423-024-01231-0","volume":"21","author":"S Chen","year":"2024","unstructured":"Chen S, Zhang P, Zhu G, Wang B, Cai J, Song L, Wan J, Yang Y, Du J, Cai Y, et al. Targeting GSDME-mediated macrophage polarization for enhanced antitumor immunity in hepatocellular carcinoma. Cell Mol Immunol. 2024;21(12):1505\u201321.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"3490_CR185","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13045-021-01207-x","volume":"14","author":"JC Lu","year":"2021","unstructured":"Lu JC, Zhang PF, Huang XY, Guo XJ, Gao C, Zeng HY, Zheng YM, Wang SW, Cai JB, Sun QM, et al. Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. J Hematol Oncol. 2021;14(1):200.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3490_CR186","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/s41467-024-45215-0","volume":"15","author":"C Liu","year":"2024","unstructured":"Liu C, Zhou C, Xia W, Zhou Y, Qiu Y, Weng J, Zhou Q, Chen W, Wang YN, Lee HH, et al. Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma. Nat Commun. 2024;15(1):1009.","journal-title":"Nat Commun"},{"issue":"2","key":"3490_CR187","doi-asserted-by":"publisher","first-page":"105","DOI":"10.36401\/JIPO-20-32","volume":"4","author":"CC Lin","year":"2021","unstructured":"Lin CC. Clinical development of Colony-Stimulating factor 1 receptor (CSF1R) inhibitors. J Immunother Precis Oncol. 2021;4(2):105\u201314.","journal-title":"J Immunother Precis Oncol"},{"issue":"4","key":"3490_CR188","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/nov245","volume":"18","author":"N Butowski","year":"2016","unstructured":"Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy foundation early phase clinical trials consortium phase II study. Neuro Oncol. 2016;18(4):557\u201364.","journal-title":"Neuro Oncol"},{"key":"3490_CR189","doi-asserted-by":"crossref","unstructured":"Razak AR, Cleary JM, Moreno V, Boyer M, Calvo Aller E, Edenfield W, Tie J, Harvey RD, Rutten A, Shah MA et al. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. J Immunother Cancer 2020, 8(2).","DOI":"10.1136\/jitc-2020-001006"},{"key":"3490_CR190","doi-asserted-by":"crossref","unstructured":"Machiels JP, Gomez-Roca C, Michot JM, Zamarin D, Mitchell T, Catala G, Eberst L, Jacob W, Jegg AM, Cannarile MA et al. Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. J Immunother Cancer 2020, 8(2).","DOI":"10.1136\/jitc-2020-001153"},{"issue":"17","key":"3490_CR191","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1158\/1078-0432.CCR-21-0903","volume":"27","author":"SA Weiss","year":"2021","unstructured":"Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Levit NS, Anderson G, et al. A phase I study of APX005M and Cabiralizumab with or without nivolumab in patients with melanoma, kidney cancer, or Non-Small cell lung cancer resistant to Anti-PD-1\/PD-L1. Clin Cancer Res. 2021;27(17):4757\u201367.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3490_CR192","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s10637-021-01088-4","volume":"39","author":"GS Falchook","year":"2021","unstructured":"Falchook GS, Peeters M, Rottey S, Dirix LY, Obermannova R, Cohen JE, Perets R, Frommer RS, Bauer TM, Wang JS, et al. A phase 1a\/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or Tremelimumab in patients with advanced solid tumors. Invest New Drugs. 2021;39(5):1284\u201397.","journal-title":"Invest New Drugs"},{"issue":"2","key":"3490_CR193","doi-asserted-by":"publisher","first-page":"73","DOI":"10.36401\/JIPO-23-16","volume":"7","author":"J Ahmed","year":"2024","unstructured":"Ahmed J, Stephen B, Yang Y, Kwiatkowski E, Ejezie CL, Pant S. Phase ib\/ii study of lacnotuzumab in combination with Spartalizumab in patients with advanced malignancies. J Immunother Precis Oncol. 2024;7(2):73\u201381.","journal-title":"J Immunother Precis Oncol"},{"issue":"3","key":"3490_CR194","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/cpt.3503","volume":"117","author":"YO Yang","year":"2025","unstructured":"Yang YO, Sokolov V, Volkova A, Liu X, Leon C, Kosinsky Y, Barker B, Zhang X, Ordentlich P, Sheng J, et al. Semimechanistic population PK\/PD modeling of axatilimab in healthy participants and patients with solid tumors or chronic Graft-Versus-Host disease. Clin Pharmacol Ther. 2025;117(3):704\u201315.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"3490_CR195","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1158\/1078-0432.CCR-21-3009","volume":"28","author":"M Johnson","year":"2022","unstructured":"Johnson M, Dudek AZ, Sukari A, Call J, Kunk PR, Lewis K, Gainor JF, Sarantopoulos J, Lee P, Golden A, et al. ARRY-382 in combination with pembrolizumab in patients with advanced solid tumors: results from a phase 1b\/2 study. Clin Cancer Res. 2022;28(12):2517\u201326.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3490_CR196","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1124\/jpet.118.254128","volume":"369","author":"F Pognan","year":"2019","unstructured":"Pognan F, Couttet P, Demin I, Jaitner B, Pang Y, Roubenoff R, Sutter E, Timsit Y, Valentin MA, Vogel B, et al. Colony-Stimulating Factor-1 antibody lacnotuzumab in a phase 1 healthy volunteer study and mechanistic investigation of safety outcomes. J Pharmacol Exp Ther. 2019;369(3):428\u201342.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"3490_CR197","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ajpath.2011.03.029","volume":"179","author":"ZA Radi","year":"2011","unstructured":"Radi ZA, Koza-Taylor PH, Bell RR, Obert LA, Runnels HA, Beebe JS, Lawton MP, Sadis S. Increased serum enzyme levels associated with Kupffer cell reduction with no signs of hepatic or skeletal muscle injury. Am J Pathol. 2011;179(1):240\u20137.","journal-title":"Am J Pathol"},{"issue":"3","key":"3490_CR198","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/1091581811401920","volume":"30","author":"T Wang","year":"2011","unstructured":"Wang T, Papoutsi M, Wiesmann M, DeCristofaro M, Keselica MC, Skuba E, Spaet R, Markovits J, Wolf A, Moulin P, et al. Investigation of correlation among safety biomarkers in serum, histopathological examination, and toxicogenomics. Int J Toxicol. 2011;30(3):300\u201312.","journal-title":"Int J Toxicol"},{"key":"3490_CR199","doi-asserted-by":"publisher","first-page":"152075","DOI":"10.1016\/j.bbrc.2025.152075","volume":"773","author":"Q Shi","year":"2025","unstructured":"Shi Q, Ren L, Papineau K, Yang X, Pang L, Oliphant JH, Schnackenberg L, Mattes W. Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations. Biochem Biophys Res Commun. 2025;773:152075.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"3490_CR200","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1634\/theoncologist.2019-0418","volume":"24","author":"E Rosenbaum","year":"2019","unstructured":"Rosenbaum E, Kelly C, D\u2019Angelo SP, Dickson MA, Gounder M, Keohan ML, Movva S, Condy M, Adamson T, McFadyen CR, et al. A phase I study of binimetinib (MEK162) combined with pexidartinib (PLX3397) in patients with advanced Gastrointestinal stromal tumor. Oncologist. 2019;24(10):1309\u2013e1983.","journal-title":"Oncologist"},{"issue":"18","key":"3490_CR201","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-24-0103","volume":"30","author":"H Gelderblom","year":"2024","unstructured":"Gelderblom H, Razak AA, Taylor MH, Bauer TM, Wilky B, Martin-Broto J, Gonzalez AF, Rutkowski P, Szostakowski B, Alcindor T, et al. CSF1R Inhibition in patients with advanced solid tumors or tenosynovial giant cell tumor: A phase I study of Vimseltinib. Clin Cancer Res. 2024;30(18):3996\u20134004.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3490_CR202","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s10637-021-01084-8","volume":"39","author":"A Dowlati","year":"2021","unstructured":"Dowlati A, Harvey RD, Carvajal RD, Hamid O, Klempner SJ, Kauh JSW, Peterson DA, Yu D, Chapman SC, Szpurka AM, et al. LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial. Invest New Drugs. 2021;39(4):1057\u201371.","journal-title":"Invest New Drugs"},{"issue":"6","key":"3490_CR203","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40261-025-01438-7","volume":"45","author":"M Haranaka","year":"2025","unstructured":"Haranaka M, Kinami K, Yang YO, Li H, Pratta M, Suzukawa K. Safety, tolerability, pharmacokinetics, and pharmacodynamics of axatilimab in healthy Japanese male participants: results from a phase 1, randomized, Double-Blind, Dose-Escalation study. Clin Drug Investig. 2025;45(6):327\u201334.","journal-title":"Clin Drug Investig"},{"key":"3490_CR204","doi-asserted-by":"crossref","unstructured":"Bissinger S, Hage C, Wagner V, Maser IP, Brand V, Schmittnaegel M, Jegg AM, Cannarile M, Watson C, Klaman I et al. Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition. Sci Transl Med. 2021, 13(598).","DOI":"10.1126\/scitranslmed.abd4550"},{"key":"3490_CR205","doi-asserted-by":"publisher","first-page":"104855","DOI":"10.1016\/j.critrevonc.2025.104855","volume":"215","author":"EI Bahbah","year":"2025","unstructured":"Bahbah EI, Attia M, Ali M. Efficacy and safety of axatilimab in chronic graft-versus-host disease: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2025;215:104855.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"21","key":"3490_CR206","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1158\/1078-0432.CCR-20-0855","volume":"26","author":"KA Autio","year":"2020","unstructured":"Autio KA, Klebanoff CA, Schaer D, Kauh JSW, Slovin SF, Adamow M, Blinder VS, Brahmachary M, Carlsen M, Comen E, et al. Immunomodulatory activity of a Colony-stimulating Factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: A phase I study. Clin Cancer Res. 2020;26(21):5609\u201320.","journal-title":"Clin Cancer Res"},{"key":"3490_CR207","doi-asserted-by":"publisher","first-page":"175883591985423","DOI":"10.1177\/1758835919854238","volume":"11","author":"R Wesolowski","year":"2019","unstructured":"Wesolowski R, Sharma N, Reebel L, Rodal MB, Peck A, West BL, Marimuthu A, Severson P, Karlin DA, Dowlati A, et al. Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and Paclitaxel in patients with advanced solid tumors. Ther Adv Med Oncol. 2019;11:1758835919854238.","journal-title":"Ther Adv Med Oncol"},{"key":"3490_CR208","doi-asserted-by":"publisher","first-page":"101514","DOI":"10.1016\/j.smim.2021.101514","volume":"54","author":"P Ordentlich","year":"2021","unstructured":"Ordentlich P. Clinical evaluation of colony-stimulating factor 1 receptor inhibitors. Semin Immunol. 2021;54:101514.","journal-title":"Semin Immunol"},{"key":"3490_CR209","doi-asserted-by":"crossref","unstructured":"Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Perez Gracia JL, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP et al. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 Atezolizumab in advanced solid tumor patients Naive or experienced for immune checkpoint Blockade. J Immunother Cancer 2022, 10(5).","DOI":"10.1136\/jitc-2021-004076"},{"issue":"4","key":"3490_CR210","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10637-023-01374-3","volume":"41","author":"EI Buchbinder","year":"2023","unstructured":"Buchbinder EI, Giobbie-Hurder A, Haq R, Ott PA. A phase I\/II study of LY3022855 with BRAF\/MEK Inhibition in patients with melanoma. Invest New Drugs. 2023;41(4):551\u20135.","journal-title":"Invest New Drugs"},{"key":"3490_CR211","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.canlet.2019.05.019","volume":"458","author":"Z Li","year":"2019","unstructured":"Li Z, Wu T, Zheng B, Chen L. Individualized precision treatment: targeting TAM in HCC. Cancer Lett. 2019;458:86\u201391.","journal-title":"Cancer Lett"},{"issue":"6","key":"3490_CR212","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s00432-024-05831-1","volume":"150","author":"S Huang","year":"2024","unstructured":"Huang S, He L, Zhao Y, Wei Y, Wang Q, Gao Y, Jiang X. TREM1(+) tumor-associated macrophages secrete CCL7 to promote hepatocellular carcinoma metastasis. J Cancer Res Clin Oncol. 2024;150(6):320.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"14","key":"3490_CR213","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41388-023-02646-1","volume":"42","author":"M Akce","year":"2023","unstructured":"Akce M, El-Rayes BF, Wajapeyee N. Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy. Oncogene. 2023;42(14):1051\u20137.","journal-title":"Oncogene"},{"issue":"4","key":"3490_CR214","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1615\/CritRevOncog.2024053580","volume":"29","author":"T Festekdjian","year":"2024","unstructured":"Festekdjian T, Bonavida B. Targeting the depletion of M2 macrophages: implication in cancer immunotherapy. Crit Rev Oncog. 2024;29(4):55\u201373.","journal-title":"Crit Rev Oncog"},{"issue":"9","key":"3490_CR215","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1097\/CAD.0000000000001480","volume":"34","author":"M El Shemerly","year":"2023","unstructured":"El Shemerly M, Zanini E, Lecoultre M, Walker PR, Kellenberger L, Lane HA, McSheehy PMJ. Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models. Anticancer Drugs. 2023;34(9):1035\u201345.","journal-title":"Anticancer Drugs"},{"issue":"9","key":"3490_CR216","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/gutjnl-2019-318419","volume":"68","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, Li CW, Lim SO, Sheng YY, Zhang Y, et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 Blockade. Gut. 2019;68(9):1653\u201366.","journal-title":"Gut"},{"issue":"30","key":"3490_CR217","doi-asserted-by":"publisher","first-page":"e2401906","DOI":"10.1002\/adhm.202401906","volume":"13","author":"KR Neupane","year":"2024","unstructured":"Neupane KR, Aryal SP, Harvey BT, Ramon GS, Chun B, McCorkle JR, Kolesar JM, Kekenes-Huskey PM, Richards CI. Organelle specific macrophage engineered vesicles differentially reprogram macrophage polarization. Adv Healthc Mater. 2024;13(30):e2401906.","journal-title":"Adv Healthc Mater"},{"key":"3490_CR218","doi-asserted-by":"crossref","unstructured":"Myojin Y, Babaei S, Trehan R, Hoffman C, Kedei N, Ruf B, Benmebarek MR, Bauer KC, Huang P, Ma C et al. Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab. Gut. 2025.","DOI":"10.1136\/gutjnl-2024-334026"},{"issue":"4suppl","key":"3490_CR219","doi-asserted-by":"publisher","first-page":"TPS465","DOI":"10.1200\/JCO.2019.37.4_suppl.TPS465","volume":"37","author":"A Wang-Gillam","year":"2019","unstructured":"Wang-Gillam A, O\u2019Reilly EM, Bendell JC, Wainberg ZA, Borazanci EH, Bahary N, O\u2019Hara MH, Beatty GL, Pant S, Cohen DJ, et al. A randomized phase II study of Cabiralizumab (cabira)\u2009+\u2009nivolumab (nivo)\u2009\u00b1\u2009chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2019;37(4_suppl):TPS465\u2013465.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3490_CR220","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ccell.2017.10.005","volume":"32","author":"V Kumar","year":"2017","unstructured":"Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, Hashimoto A, Vonteddu P, Behera R, Goins MA, et al. Cancer-Associated fibroblasts neutralize the Anti-tumor effect of CSF1 receptor Blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell. 2017;32(5):654\u201368. e655.","journal-title":"Cancer Cell"},{"issue":"12","key":"3490_CR221","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/1535-7163.MCT-16-0157","volume":"15","author":"LP Pradel","year":"2016","unstructured":"Pradel LP, Ooi CH, Romagnoli S, Cannarile MA, Sade H, Ruttinger D, Ries CH. Macrophage susceptibility to emactuzumab (RG7155) treatment. Mol Cancer Ther. 2016;15(12):3077\u201386.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"3490_CR222","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12943-023-01884-x","volume":"22","author":"D Djureinovic","year":"2023","unstructured":"Djureinovic D, Weiss SA, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto AL, Wei W, Anderson G, et al. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. Mol Cancer. 2023;22(1):182.","journal-title":"Mol Cancer"},{"issue":"20","key":"3490_CR223","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1158\/1078-0432.CCR-21-0810","volume":"27","author":"CC Foster","year":"2021","unstructured":"Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, et al. Phase I study of stereotactic body radiotherapy plus nivolumab and urelumab or Cabiralizumab in advanced solid tumors. Clin Cancer Res. 2021;27(20):5510\u20138.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3490_CR224","doi-asserted-by":"publisher","first-page":"152805","DOI":"10.1016\/j.imbio.2024.152805","volume":"229","author":"J Tang","year":"2024","unstructured":"Tang J, Ming L, Qin F, Qin Y, Wang D, Huang L, Cao Y, Huang Z, Yin Y. The heterogeneity of tumour-associated macrophages contributes to the clinical outcomes and indications for immune checkpoint Blockade in colorectal cancer patients. Immunobiology. 2024;229(3):152805.","journal-title":"Immunobiology"},{"issue":"1","key":"3490_CR225","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12885-023-10675-y","volume":"23","author":"K Yang","year":"2023","unstructured":"Yang K, Yang T, Yu J, Li F, Zhao X. Integrated transcriptional analysis reveals macrophage heterogeneity and macrophage-tumor cell interactions in the progression of pancreatic ductal adenocarcinoma. BMC Cancer. 2023;23(1):199.","journal-title":"BMC Cancer"},{"issue":"21","key":"3490_CR226","doi-asserted-by":"publisher","first-page":"21455","DOI":"10.1021\/acsnano.3c06233","volume":"17","author":"R Huang","year":"2023","unstructured":"Huang R, Zhou P, Chen B, Zhu Y, Chen X, Min Y. Stimuli-Responsive nanoadjuvant rejuvenates robust immune responses to sensitize cancer immunotherapy. ACS Nano. 2023;17(21):21455\u201369.","journal-title":"ACS Nano"},{"key":"3490_CR227","doi-asserted-by":"crossref","unstructured":"Lim C, Hwang D, Yazdimamaghani M, Atkins HM, Hyun H, Shin Y, Ramsey JD, Radler PD, Mott KR, Perou CM et al. High-Dose Paclitaxel and its combination with CSF1R inhibitor in polymeric micelles for chemoimmunotherapy of triple negative breast cancer. Nano Today 2023, 51.","DOI":"10.1016\/j.nantod.2023.101884"},{"issue":"4","key":"3490_CR228","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1021\/acsnano.3c10037","volume":"18","author":"Y Hu","year":"2024","unstructured":"Hu Y, Nie W, Lyu L, Zhang X, Wang W, Zhang Y, He S, Guo A, Liu F, Wang B, et al. Tumor-Microenvironment-Activatable nanoparticle mediating Immunogene therapy and M2 Macrophage-Targeted inhibitor for synergistic cancer immunotherapy. ACS Nano. 2024;18(4):3295\u2013312.","journal-title":"ACS Nano"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03490-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03490-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03490-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:50:00Z","timestamp":1757343000000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03490-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":229,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3490"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03490-9","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"227"}}